Revenue: $3,873,993 in QQ1 2026; YoY growth +21.89%; QoQ growth +7.04%. Gross Profit: $3,116,800; Gross Margin 80.45%; YoY gross profit growth +37.16%; QoQ +12.77%. EBITDA: $333,337; EBITDA margin 8.60%; Operating Income: $281,945; Operating Margin 7.28% (vs. negative working capital pressures elsewhere). Net Income: -$671,977; Net Margin -17.35%; EPS -$0.029; EPS Diluted -$0.029; Weighted Avg Shares 26,284,734.
Cash Flow and liquidity: Net cash provided by operating activities -$373,389; Free cash flow -$373,389; Cash and cash equivalents at period end $391,292. Balance sheet health: Total assets $6,037,319; Total liabilities $36,835,946; Total stockholders’ equity -$30,798,627; Current assets $5,144,540 vs. Current liabilities $21,806,321; Current ratio ~0.24; Quick ratio ~0.10. Debt profile: Short-term debt $13,587,017; Long-term debt $504,344; Net debt $12,896,689; Cash burn still evident despite EBITDA positivity. Revenue mix and profitability signals suggest improving gross margins, but the cash burn and leverage risk dominate near-term investment considerations.
Competitive benchmarking and industry context: In peer comparisons within the medical devices and cardiovascular monitoring space, Biotricity’s gross margin is favorable (approx. 80%), but peers generally exhibit more favorable liquidity profiles or larger scale. For example, selected peers show mixed profitability with higher losses or stronger cash positions; Biotricity’s current liquidity metrics indicate a material gap to sustain ongoing operations without external financing. Net debt and negative equity heavily weigh on valuation versus peers with more balanced balance sheets. Relative to revenue scale, BTCY’s quarterly run-rate remains modest, limiting near-term ability to delever without significant strategic actions or debt restructuring.